Showing results (271-280 of 298) with videos related to
Sort By:
Pageof 30
Translational Lung Cancer Research|April 15, 2026
Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort studyAkio Nomura, Takeshi Masuda, Kiyofumi Shimoji, et al.JTO Clinical and Research Reports|February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLCDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.Cancer Cell International|November 15, 2022
Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistanceAyumi Kanemaru, Satoru Shinriki, Mimi Kai, et al.Scientific Reports|November 13, 2023
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancerTakeshi Masuda, Satoru Miura, Yuki Sato, et al.Medicina (Kaunas, Lithuania)|October 28, 2023
Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic RhinosinusitisTakashi Oda, Hiroshi Iwamoto, Sachio Takeno, et al.Cancers|December 23, 2022
Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung CancerWakako Daido, Takeshi Masuda, Nobuki Imano, et al.Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.Journal of Thoracic Disease|April 11, 2020
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancerTakeshi Masuda, Kazunori Fujitaka, Nobuhisa Ishikawa, et al.The EMBO Journal|March 28, 2026
CDKAL1 dysfunction impairs lysine codon translation in podocytes and accelerates chronic kidney diseaseHiroko Nagata, Yu Nagayoshi, Takeshi Chujo, et al.JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.Pageof 30